ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

33678 results sorted by trial registration date.
  • The Health Anxiety Program: a pilot trial of an online program for people who worry excessively about their health

    The project aims to evaluate the acceptability and clinical efficacy of the online Health Anxiety Program. Up to 25 people with elevated health anxiety (either IAD or SSD) will be assigned to the active treatment group. The treatment group will commence the Health Anxiety Program immediately. The efficacy of the Health Anxiety Program will be determined by comparing the health anxiety symptom levels before and after treatment, and at 3 month follow-up.

  • A pilot study to assess feasibility, safety and efficacy of artificially introducing an air-pleura interface for detection of pleural nodules by computed tomography

    This study will evaluate the use of an artificial air-pleura interface by introducing air into the chest for a computed tomography (CT) scan to detect abnormalities in patients with known or suspected malignant pleural effusion. Who is it for? You may be eligible to join this study if you are aged 18 years or above, have known or suspected malignant pleural effusion and have a chest drain in-situ. Study details: All participants will have two CT scans: one standard CT scan and one CT scan with an artificial air-pleura interface. The artificial air-pleura interface will be created by introducing 500mL of air via an in-situ chest drain [such as intercostal catheter (ICC) or indwelling pleural catheter (IPC)]. The air is introduced using a syringe connected to the chest drain. The findings on pleura detected by the two CT scans will be compared. No previous studies have specifically assessed pleural abnormalities through this technique. We hypothesize for this study that artificially creating an air-pleura interface will make the small pleural nodules (~1cm) more conspicuous and will allow significantly better detection of previously undetectable pleural abnormalities/ nodules by CT scan.

  • The Effects Of Dual, Inhaled Long-Acting Bronchodilators on Complex Lung Mechanics in Chronic Obstructive Pulmonary Disease

    This projects aims to study the effects of different inhaled bronchodilator medications used in the management of COPD. Clinical trials have demonstrated their effects on the large airways of the lungs, however their effects on the small airways are not yet known. This project will use sensitive tests of small airway function to identify the effects of bronchodilator therapy on the small airways in COPD. Specifically, we aim to determine if two different classes of bronchodilators have a greater effect when given in combination than when given alone. We hope to use this information to enhance our knowledge of how these medications work, which may help us improve the treatment of patients with COPD.

  • TROG 15.01 (SPARK) Efficacy of Kilovoltage Intrafraction Monitoring (KIM) in men with prostate cancer undergoing stereotactic prostate radiotherapy

    This study will determine the efficacy of the addition of Kilovoltage Intrafraction Monitoring during stereotactic prostate adaptive radiotherapy in prostate cancer patients. Who is it for? You may be eligible to join this study if you are aged 18 years or above and have histologically proven prostate adenocarcinoma with low or intermediate disease risk. Study details All participants will receive multi-fraction stereotactic prostate adaptive radiotherapy at 36.25 Gy in 5 fractions over 2-5 weeks. A new technology, known as Kilovoltage Intrafraction Monitoring (KIM), will be used which allows images of a tumour to be taken in real-time while the treatment is occurring. This enables strategies such as patient shifting or beam shifting during treatment which could potentially improve the accuracy of the treatment and reduce the patient’s side effects. In addition, due to the accuracy of KIM in targeting tumours, the number of treatment sessions this group of patients will require will be reduced to five as opposed to the 40 sessions required using more conventional treatment methods. Efficacy of KIM will be assessed by the dose accumulation method for each session. Participants will be followed for up to 2 years, in order to determine patient treatment outcomes, and toxicity. The researchers expect this trial to result in better targeted prostate cancer patient outcomes with lower toxicity. The potential application of KIM to other tumour sites will pave the way for additional trials with Australasian radiation oncology leading the world.

  • Novel approaches to manage glucocorticoid-induced diabetes in hospital inpatients

    High dose steroids can raise blood glucose levels. These can cause infections, prolong hospital stay and even rarely result in death. Little is known about the best way to manage patients with ‘steroid diabetes’. We will study various approaches to manage high glucose levels in patients treated with steroids in hospital. We will use minimally invasive continuous glucose monitoring, a contemporary technology, to compare and evaluate in detail two different treatment schedules. One intervention will combine longer acting and mealtime insulin (conventional regimen), and the other will combine liraglutide, a newer non-insulin injection, together with longer acting insulin. The results of this study will provide important objective pilot data on management of patients with ‘steroid diabetes’ in hospital.

  • Randomised Controlled Trial of Cognitive Behaviour Therapy for Journalists to Reduce Posttraumatic Stress Disorder

    The rationale of the study is to evaluate the benefits of Cognitive Behaviour Therapy for reducing PTSD in journalists. This study compares the relative effectiveness of (a) Cognitive Behaviour Therapy provided by therapists via telemedicine to journalists compared to the same components which journalists read in manuals provided to them.

  • Great Leaders, Active Students.- Evaluating the impact of a Peer Leadership Program for Grade 6 students on the movement skill competency and physical activity levels of students in Kindergarten, Grade 1 and 2

    Competency in a range of movement skills (e.g. kicking, running, throwing) provides the foundation for an active lifestyle and developing leadership skills is important for children of all ages. It may also serve as a protective factor against the decline in physical activity typically observed during adolescence. Our proposed project will evaluate the impact of the Peer Leadership Program for Grade 6 students and on the movement skill competency and physical activity levels of students in Kindergarten, Grade 1 and 2. Our aim is to recruit two primary schools with 40-60 Grade 6 students, approximately 180 Kindergarten, Grade 1, Grade 2 students. Schools who agree to participate will be allocated to receive the Peer Leadership program in Term 1, week 10, 2015 or Term 3, week 1, 2015. Members of the research team will deliver the 3-hour Peer Leadership Program during school sport time, which will provide Grade 6 students with the skills to run physical activity sessions during timetabled physical education, lunch and recess for kindergarten, Grade 1 and 2 students. The study will be evaluated over a 10-week period and students in BOTH groups will complete evaluation measures at baseline (before the program begins) and 10-weeks (post program).

  • Stereotactic Hypofractionated body radiosurgery for Oligometastatic Renal cell Tumours upfront, with Systemic Targeted agents On Progression

    This study aims to investigate the side effects, safety, and effectiveness of stereotactic hypofractionated body radiosurgery for oligometastatic renal cell tumours. Who is it for? You may be eligible to join this study if you are aged 18 years or above and have histologically or cytologically confirmed renal cell carcinoma and 1 to 3 extracranial metastases (with no prior systemic targeted therapy) or 4 to 6 extracranial metastases in patients currently on systemic targeted therapy AND no more than 1 to 3 progressing metastases. Study details Stereotactic ablative body radiotherapy (SABR) is a new form of cancer treatment involving high precision radiotherapy. SABR treatment appears to be effective in controlling cancer in other sites elsewhere in the body, including the lung, spine, liver and kidney. We aim to test the ability of this new technique to control cancers that have spread beyond the kidney to other organs or to the bones. This study will involve discussing your medical history and progress of your renal cell tumour with the doctor. A whole body bone scan and CT scan of the chest, abdomen and pelvis will be performed to confirm the location and number of secondary deposits of the tumour prior to treatment and at follow up visits. In addition to the bone and CT scans, an additional scan called a diffusion and perfusion MRI will be used before treatment and 3 months after treatment to investigate the changes in cancer blood flow before and after treatment. Up to three sessions of SABR treatment will be performed, depending on the location of your secondary cancer deposits. As part of the study, blood samples will be taken before and after treatment at 5 timepoints over a period of approximately 3-4 months. Questionnaires looking at quality of life and pain will be completed before treatment, and at each follow up visit. Follow up visits will be performed at approximately 1 month, and every 3 months until 2 years after the radiotherapy treatment. This is the first step of the research, and is a ‘pilot’ study. If the technique is shown to be both feasible and tolerable for this pilot study of 30 patients, we would then look at expanding this study.

  • Double-blinded randomised trial of prophylactic dexamethasone versus placebo in stereotactic radiotherapy to 1-5 brain metastases

    Update This study aims to assess if dexamethasone influences the development of symptoms, if any during stereotactic radiotherapy (SRT) to brain metastases. Who is it for? You may be eligible to join this study if you are aged 18 years or above, have 1-5 brain metastases with at least one lesion planned for SRT, and not on dexamethasone for at least 7 days prior to SRT. Study details: There are no clear guidelines on who would benefit from prophylactic (ie. as a precaution before any symptoms develop) dexamethasone during SRT to brain metastases. Some clinicians may choose to prescribe prophylactic dexamethasone to prevent or minimize any local swelling during radiotherapy. Others may not, as not all patients will develop symptoms. To evaluate this, we are randomising patients to having 4 mg oral dexamethasone (on days of SRT and 1 day after) or placebo. We are also studying the effect of treatment on patient’s quality of life. It is hypothesised that patients in the placebo arm may develop symptoms following SRT. The results of the study will guide clinicians whether prophylactic dexamethasone is beneficial in a selected group of patients having stereotactic radiation for brain metastases.

  • Partners in Parenting: Evaluating an online personalised parenting program

    This study aims to evaluate the effects of an individually-tailored web-based parenting program on parenting behaviours associated with adolescent depression and anxiety disorders. The program is designed to provide parents with (1) personalised feedback about their current parenting, including what they are doing well and areas that they can improve in order to reduce their teenager’s risk of depression and anxiety, and (2) specific modules of the web-based parenting intervention recommended based on their survey responses to support them in making changes to identified areas for improvement in their parenting. We aim to find out whether this program can help improve parenting behaviours associated with adolescent depression and anxiety, and in turn reduce risk of depression and anxiety in teenagers.

Tags:
  • Finding clinical trials